Novartis judgment: Let's make research a priority, rest will follow
11 years, 11 months ago

Novartis judgment: Let's make research a priority, rest will follow

Firstpost  

Our academic and research institutions have to make research a priority and the government has to liberally fund them. In the report, multinational drug company Novartis said it wouldn’t invest in R&D in India because the country doesn’t have the ecosystem for innovation! The report also didn’t say that all these years no MNC, except AstraZeneca, has made R&D investments in India. Sometimes, the turn-overs of the number one and two pharma companies in India don’t even add up to the turnover of a single MNC drug. Beyond research, the country also has to invest heavily on the complex processes of converting research knowledge into commercial products, including clinical trials and modern drug regulatory regimes.

India Research Drugs Indian Manufacturers Institutions Mnc Novartis Generics Glivec Nexavar  priority  research  judgment  novartis  follow  india  institutions  lets  rd  drugs  manufacturers  mnc  generics  public  rest

History of this topic

Dr Reddy's likely to pick up Novartis AG's total 70.68% stake in Novartis India: Report
1 year, 1 month ago

Dr Reddy's likely to pick up Novartis AG's total 70.68% stake in Novartis India: Report

Hindustan Times  

Hyderabad-based Dr Reddy's Laboratories is reportedly looking to pick up Novartis AG's entire stake in Novartis India. Swiss pharmaceutical firm Novartis AG will be carrying out a ‘strategic review’ of Novartis India, its listed entity in the country. Novartis India is the listed entity in the country of Novartis AG, a Swiss pharmaceutical major The ‘strategic review’ includes an assessment …

Mega schemes for pharma development, med-tech innovation and reducing dependency API import to be announced next month
1 year, 7 months ago

Mega schemes for pharma development, med-tech innovation and reducing dependency API import to be announced next month

The Hindu  

The Ministry of Chemicals and Fertilizers will soon announce a ₹5,000-crore research programme aimed at reducing India’s import dependency on Active Pharmaceutical Ingredients and promoting discovery of new drug molecules. “The policies aim to engage nine established pharmaceutical companies in impact research across six priority areas with prestigious government institutes. It also approved a new Scheme for Promotion of Research …

Coming Soon: Research-linked Incentive Scheme to Rejuvenate Global Image of Indian Pharma Market
2 years, 8 months ago

Coming Soon: Research-linked Incentive Scheme to Rejuvenate Global Image of Indian Pharma Market

News 18  

With an aim of improving India’s position in the global pharmaceuticals market on the innovation index, the Narendra Modi government is preparing to launch a “research-linked incentive scheme”, News18.com has learnt. Planning India’s shift away from a low-value, high-volume player to a high-value, high-volume player in the global pharma market, the government is in discussions over the proposed scheme with …

Why Novartis case will help innovation
11 years, 11 months ago

Why Novartis case will help innovation

The Hindu  

On April 1, 2013, the Supreme Court upheld the Intellectual Property Appellate Board’s decision to deny patent protection to Novartis’s application covering a beta crystalline form of imatinib —the medicine Novartis brands as Glivec, and which is very effective against the form of cancer known as chronic myeloid leukaemia. Thirdly, the Supreme Court judgment effectively recast Indian patent law as …

Drug R&D: Why India can easily ignore Novartis blackmail
11 years, 11 months ago

Drug R&D: Why India can easily ignore Novartis blackmail

Firstpost  

India is a country where pharma companies can do research and development at lower cost. So, big pharmas would not want to invest,” Ranjit Shahani of Novartis India said yesterday, reacting to the Supreme Court order rejecting the Swiss drug major’s patent plea for cancer drug Glivec. According to a study conducted by the Tufts Center for the Study of …

Novartis judgement will hit investments in medicine: US commerce body
11 years, 11 months ago

Novartis judgement will hit investments in medicine: US commerce body

Firstpost  

Supreme Court of India’s decision to deny patent to Swiss firm Novartis for its cancer drug Glivec will negatively impact the ability of companies to invest in medical and technological advancements, the US Chamber of Commerce said. Washington: Supreme Court of India’s decision to deny patent to Swiss firm Novartis for its cancer drug Glivec will negatively impact the ability …

Landmark verdict, say pharma bodies
11 years, 11 months ago

Landmark verdict, say pharma bodies

The Hindu  

The Indian pharmaceutical industry and health aid agencies have welcomed the judgment of the Supreme Court which has upheld the refusal by the Patent Office to grant multi-national pharma giant Novartis a patent for the beta-polymorphic form of imatinib mesylate sold as Glivec and used in the treatment of cancer. “This is a landmark judgment that will serve to set …

Discover Related